Groundbreaking genomic test could save millions of breast cancer patients from chemotherapy – The Guardian & more related News Here
Groundbreaking genomic test could save millions of breast cancer patients from chemotherapyGuardian VeraCyte genomic test identifies breast cancer patients who can skip chemoreuters The landmark OPTIMA trial provides practice-changing evidence that Verasight’s ProSigna test identifies patients with high-risk breast cancer who can safely avoid chemotherapy.business wire How Investors Are Reacting to Verasight (VCYT) ASCO Phase…
